Relacorilant Patent Expiration
Relacorilant was first introduced by Corcept Therapeutics Inc
Relacorilant Patents
Given below is the list of patents protecting Relacorilant, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lifyorli (copackaged) | US12152028 | Methods Of Preparing Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators | Dec 22, 2041 | Corcept Therap |
| Lifyorli (copackaged) | US11285145 | Concomitant Administration Of Glucocorticoid Receptor Modulator Relacorilant And Paclitaxel, A Dual Substrate Of Cyp2C8 And Cyp3A4 | May 26, 2041 | Corcept Therap |
| Lifyorli (copackaged) | US12589094 | May 26, 2041 | Corcept Therap | |
| Lifyorli (copackaged) | US11464764 | Pharmaceutical Formulations Containing Relacorilant, A Heteroaryl-Ketone Fused Azadecalin Compound | Apr 14, 2040 | Corcept Therap |
| Lifyorli (copackaged) | US11925626 | Pharmaceutical Formulations Containing Relacorilant, A Heteroaryl-Ketone Fused Azadecalin Compound | Dec 18, 2039 | Corcept Therap |
| Lifyorli (copackaged) | US12514849 | Pharmaceutical Formulations Containing Relacorilant, A Heteroaryl-Ketone Fused Azadecalin Compound | Dec 18, 2039 | Corcept Therap |
| Lifyorli (copackaged) | US10456392 | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators | May 24, 2033 | Corcept Therap |
| Lifyorli (copackaged) | US11576907 | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators | May 24, 2033 | Corcept Therap |
| Lifyorli (copackaged) | US8859774 | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators | May 24, 2033 | Corcept Therap |
| Lifyorli (copackaged) | US9273047 | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators | May 24, 2033 | Corcept Therap |
Relacorilant's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List